CitraFlow for Vascular Access

Product Information

CitraFlow and CitraFlow PLUS prefilled syringes offer innovative solutions for locking indwelling catheters and vascular access devices, providing safe alternatives to heparin. Each product is designed to address specific clinical needs: CitraFlow is currently not cleared by the US FDA

• CitraFlow 4% SF: A proven alternative to heparin, these syringes use 4% sodium citrate to lock indwelling catheters. They are safe for patients with suspected or confirmed Heparin-Induced Thrombocytopenia (HIT) and avoid risks associated with systemic heparinization.
• CitraFlow 30% SF: Prefilled with 30% sodium citrate, these syringes offer anticoagulant and antimicrobial properties, making them effective for locking vascular access devices. They provide a safe option for patients at risk of HIT and help prevent systemic heparinization complications.
• CitraFlow 46.7% SF: Containing 46.7% sodium citrate, these syringes deliver enhanced anticoagulant and antimicrobial benefits for locking vascular access devices. Like other CitraFlow products, they are safe for patients with HIT and avoid systemic heparinization risks.
• CitraFlow PLUS: Combines the anticoagulant properties of sodium citrate with the antimicrobial effects of ethanol in one syringe. This dual-action solution prevents biofilm formation, reduces the risk of catheter-related bloodstream infections (CRBSI), and serves as a safe, effective alternative to heparin.